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Objectives: This study aimed to assess outcomes in patients who underwent hepatic resection for
colorectal liver metastases (CRLM) with subcentimetre indeterminate pulmonary nodules (IPN) and to
devise a management pathway for these patients.
Methods: Patients undergoing CRLM resection from January 2006 to December 2010 were included.
Survival differences following liver resection in patients with and without IPN were determined.
Results: A total of 184 patients were included, 30 of whom had IPN. There were no significant differ-
ences between the IPN and non-IPN groups in terms of demographics, surgery and pathological factors.
There were no significant differences between patients with and without IPN with respect to disease-free
(P = 0.190) and overall (P = 0.710) survival. Fifteen patients with IPN progressed to metastatic lung disease
over a median period of 10 months (range: 3–18 months); six of these patients underwent lung resection.
Of the remaining 15 patients with IPN, eight showed no IPN progression and subsequent CT scans did
not identify IPN in the remaining seven.
Conclusions: Colorectal liver metastases patients with IPN who have resectable disease should be
treated with liver resection and should be subject to intensive surveillance post-resection. Although 50%
of these patients will progress to develop lung metastases, this does not appear to influence survival
following liver resection.
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Introduction
Hepatic resection has become the treatment of choice in resec-
table colorectal liver metastasis (CRLM) and is associated with
longterm survival in these patients. Around 25% of patients
have synchronous liver metastases at presentation and a further
20% subsequently develop metachronous liver disease, usually
within 2 years of resection of the primary tumour.1–3 Despite the
variability in the selection criteria of patients with CRLM for
hepatic resection, 5-year survival rates of up to 58% have been
reported.4–9
Current preoperative staging of patients with suspected CRLM
and surveillance protocols following the resection of colorectal
primary disease includes computed tomography (CT) of the
thorax, abdomen and pelvis.10 The main aim is to determine
the extent of disease, including intra- and extrahepatic disease
because management strategies for these patients range from
potentially curative hepatic and/or lung resection to palliative
chemotherapy. Following the detection of CRLM, most hepato-
biliary units will also perform magnetic resonance imaging
(MRI) of the liver to elucidate further smaller liver metastases
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not demonstrated on CT. A major role of contrast-enhanced CT
imaging is to identify sites of extrahepatic disease in lymph nodes,
peritoneum and lungs, which can potentially alter the manage-
ment strategy in these patients.
In addition, preoperative CT scans may detect subcentimetre
indeterminate pulmonary nodules (IPN) in patients with resect-
able CRLM. It can be difficult to interpret these findings as
IPN can be found in up to 25% of the general population.11 The
presence of extrahepatic disease has traditionally been regarded as
a contraindication for liver resection because it has been associ-
ated with poorer outcomes.12 Because of the characteristics of
IPN, further diagnostic imaging, such as positron emission
tomography (PET), has been suggested in some studies.9,11
However, the small size of IPN means that PET may fail to differ-
entiate metastatic disease from a benign inflammatory process. To
date, there is no consensus view on whether these patients should
be managed using further imaging prior to hepatic resection, by
delaying or abandoning hepatic resection, or by proceeding with
hepatic resection and intensive postoperative surveillance.
The aim of this study was to assess outcomes in patients who
underwent potentially curative hepatic resection for CRLM with
IPN. The secondary aim was to devise a management pathway for
these patients.
Materials and methods
Patients
Patients with CRLM undergoing hepatic resection at the Hepato-
biliary and Pancreatic Unit, Queen’s Medical Centre (QMC),
Nottingham University Hospitals National Health Service (NHS)
Trust, Nottingham, UK, during the 5-year period from January
2006 to December 2010, were identified from a prospectively
maintained hepatobiliary database. Patients who underwent
primary hepatic resection with curative intent in the presence of
subcentimetre IPN during the study period were included in the
analysis. Patients with pulmonary nodules that were characteristic
of malignant lesions, benign calcified lesions or granulomas were
excluded from this study.
Collated data included patient demographics, laboratory analy-
ses, types of surgical resection, histopathology analyses and clini-
cal outcomes. Preoperative radiological assessment included a CT
scan of the thorax, abdomen and pelvis, and MRI of the liver.
Contrast-enhanced images of the thorax, abdomen and pelvis
were obtained using multi-row detector CT scanners with colli-
mation of 2.0–0.625 mm using standardized protocols. The scans
were performed from just above the superior aspect of the lungs to
below the ischial tuberosities. Contiguous axial images with a
thickness of 1.5–8.0 mm were reconstructed from the data. Oral
contrast medium was accompanied by 100 ml i.v. contrast admin-
istered through a peripheral vein at an average rate of 3 ml/s
(Niopam 300; Bracco UK Ltd, High Wycombe, UK). All preop-
erative and subsequent surveillance CT scans documenting IPN
were reviewed by a consultant radiologist (WKD) with an interest
in hepatobiliary radiology.
Radiologic characteristics of IPN were assessed with respect to
number, size and laterality. Prior to 2009, IPN progression was
determined using RECIST (response evaluation criteria in solid
tumours) Version 1 criteria.13 Since 2009, RECIST Version 1.1
criteria have been used.14 Indeterminate pulmonary nodules were
considered to be malignant based on a radiological and/or histo-
logical diagnosis of malignancy, both of which satisfy the diagnos-
tic criteria for metastatic pulmonary disease in colorectal cancer.
Surgery
Parenchymal transection was performed using the Cavi-Pulse
ultrasonic surgical aspirator (CUSA®; Model 200T, Valley Lab.,
Boulder, CO, USA). Intraoperative ultrasound was performed to
confirm the findings of preoperative imaging and to assist in
surgical planning. The number of hepatic (Couinaud15) segments
resected was determined by the procedure performed as stated
using the Brisbane nomenclature.16 Type of surgical procedure
was dependent on the resection of all macroscopic disease and
on achieving a clear resection margin while preserving sufficient
remnant liver. The extent of hepatic resection in this study
was classified under two categories according to whether the
procedure involved less than a hemi-hepatectomy, or a hemi-
hepatectomy or more.
All patients with IPN were declared to show pulmonary
metastases during the follow-up period and were deemed to be
resectable based on the location and number of metastases. These
patients were referred to the thoracic surgery department for
consideration of resection.
Follow-up
Patients were followed up in specialist hepatobiliary clinics. Fol-
lowing an initial postoperative review at 1 month, all patients were
examined in outpatient clinics at 3, 6, 12, 18 and 24 months and
annually thereafter. At each clinical review, carcinoembryonic
antigen (CEA) levels were assessed. All patients in this study
underwent follow-up for a minimum of 1 year following hepatic
resection for CRLM.
Surveillance imaging included CT scans of the thorax, abdomen
and pelvis. Patients underwent 6-monthly CT scans during the first
2 years postoperatively, followed by annual CT scans thereafter.
Liver MRI was used to characterize suspicious hepatic lesions
demonstrated on CT. The development of symptoms of recurrence
at any time-point prompted an earlier review than scheduled.
Following detection of recurrences on surveillance imaging,
all patients were discussed in a multidisciplinary meeting that
included hepatobiliary surgeons, an oncologist, a radiologist and a
pathologist. Patients with non-resectable disease were referred to
the oncologist and patients who were suitable for further surgery
underwent liver and/or lung resection within an average of 4
weeks. Overall and disease-free survival data were recorded.
Disease-free survival was defined as the time from primary
hepatic resection to the first documented recurrence of disease on
imaging. Overall survival was defined as the time between the date
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of primary hepatic resection and the date of death or most recent
date of follow-up if the patient was still alive.
Statistical analysis
Categorical data were presented as frequencies and percentages.
The Kaplan–Meier method was used to assess actuarial survival
and disease-free survival. Statistical analyses were performed
using spss Version 16.0 (SPSS, Inc., Chicago, IL, USA). Statistical
significance was taken at the 5% level.
Results
Patient demographics, surgical procedures and
pathological data
During the study period, 184 patients underwent primary hepatic
resection for CRLM at QMC, of whom 30 (16.3%) demonstrated
IPN on preoperative staging CT. The majority of patients in this
study were male (n = 113, 61.4%). Synchronous disease was
present in 74 (40.2%) patients. Six (3.3%) patients underwent
neoadjuvant oxaliplatin-based chemotherapy prior to liver resec-
tion. Demographics and clinical factors with respect to the pres-
ence of IPN are summarized in Table 1. Major hepatic resection
(hepatectomy or more) was performed in 92 (50.0%) patients,
with no postoperative deaths. Negative margin (R0) resection was
achieved in 145 (78.8%) patients.
During the study period, 54 (29.3%) patients died of recurrent
disease. The median follow-up period in the remaining patients
was 27 months (range: 12–71 months).
Indeterminate pulmonary nodules
Staging CT showed IPN in 30 (16.3%) patients. No significant
differences in demographics, extent of hepatic resection, R0 resec-
tion rate, or size and number of liver metastases were observed in
patients with and without IPN. The majority of patients had
only one IPN (n = 25, 83.3%). Three patients had two IPNs and
two patients had more than two IPNs. Two (6.7%) patients had
bilateral IPN.
Of the 30 patients in whom IPN was detected on preoperative
CT imaging, six (20.0%) underwent further diagnostic imaging
in the form of a PET scan (Fig. 1). However, none of these six
patients showed an increase in uptake of the IPN significant
enough to suggest lung metastasis. In three of these six patients,
progression of the IPN during surveillance was apparent. These
patients were treated with lung resection (n = 1) and palliative
chemotherapy (n = 2). The other three patients did not show any
disease progression of IPN.
Of the 24 patients who did not undergo a pre-liver resection
PET scan, 12 (50.0%) demonstrated progression of IPN, two of
whom showed liver disease recurrence. Five of the 10 patients in
whom IPN progressed without liver recurrence underwent lung
resection and metastatic lung disease was confirmed by histology.
Overall, 50.0% (n = 15) of patients with IPN were ultimately
identified as having metastatic lung disease over a median period
of 10 months (range: 3–18 months); six of these patients (40.0%)
underwent lung resection. All of the lesions that progressed
were found to represent lung metastases. Nine patients with IPN
identified as metastases were inoperable as a result of the number
and location of metastases, and were treated with palliative
chemotherapy.
In the remaining 15 (50.0%) patients, no progression of IPN
was observed in eight patients and no IPN was identified on
surveillance imaging in seven patients over a median follow-up of
27 months (range: 12–64 months). Of note, none of the eight
patients in whom IPN did not progress underwent lung resection.
Disease recurrence and survival
In this cohort of 30 patients with IPN, median disease-free and
overall survival were 17 months and 25 months, respectively. Rates
of 1-, 3- and 5-year disease-free survival in patients with IPN were
56.3%, 31.4% and 31.4%, respectively. Of the 154 patients without
IPN, 71 (46.1%) patients remained disease-free. Rates of 1-, 3- and
5-year disease-free survival in patients without IPN were 70.5%,
41.4% and 35.0%, respectively. There was no significant difference
Table 1 Demographic, clinical and pathological factors in patients with and without indeterminate pulmonary nodules (IPN) (n = 184)
Demographic, clinical and
pathological factors
No IPN (n = 154) IPN (n = 30) P-value
Demographic factors, n (%)
Age 65 years 88 (57.1%) 18 (60.0%) 0.772
Male gender 97 (63.0%) 16 (53.3%) 0.320
Synchronous presentation 58 (37.7%) 16 (53.3%) 0.109
Extent of resection, n (%)
Hemi-hepatectomy or more 73 (47.7%) 19 (63.3%) 0.118
Histopathological factors, n (%)
Largest tumour size 5 cm 47 (30.5%) 12 (40.0%) 0.309
Solitary hepatic metastases 77 (50.0%) 17 (56.7%) 0.504
Resection margin [R0 (1 mm)] 124 (80.5%) 21 (70.0%) 0.197
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in disease-free survival between the IPN and non-IPN groups
(P = 0.190) (Fig. 2).
One-, 3- and 5-year overall survival rates in patients without
IPN were 94.7%, 65.1% and 48.1%, respectively; those in patients
with IPN were 90.0%, 59.0% and 50.5%, respectively. There were
no significant differences in overall survival between the two
groups (P = 0.710) (Fig. 3).
Discussion
At present, hepatic resection in combination with systemic che-
motherapy is the treatment modality of choice for CRLM. Never-
theless, hepatic resection in the presence of concomitant
extrahepatic disease is associated with a poorer outcome, particu-
larly in patients with peritoneal or portal lymph node disease.12
However, resection of pulmonary colorectal metastases has
been associated with improved longterm survival, particularly in
patients with a solitary metastasis that is suitable for anatomical
resection.17
Improvements in CT imaging have increased findings of IPN in
patients with resectable CRLM, although the clinical significance
of these findings remains to be determined. In a series of 439
patients with resectable primary colorectal cancer, Brent et al.
observed that only five (11%) of 45 patients in whom indetermi-
nate lung lesions were shown on preoperative CT prior to resec-
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Figure 1 Outcomes in patients undergoing initial hepatic resection and surveillance with respect to the presence of indeterminate pulmonary
nodules (IPN). CRLM, colorectal liver metastasis; PET, positron emission tomography
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Figure 2 Differences in disease-free survival in patients with and
without indeterminate pulmonary nodules (IPN)
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tion of the primary colorectal tumour had progression of lung
disease suggesting metastatic disease.18 The authors concluded
that as only a small proportion of patients with IPN progressed to
definite metastases, patients should be offered potentially curative
resection of colorectal primary disease.18 Maithel et al. reported a
high rate of IPN (43%, n = 68) detected on staging CT in patients
suitable for hepatic resection for CRLM.19 Of these 68 patients
with indeterminate lung lesions, 35% (n = 24) were confirmed
to have metastatic lung disease according to a radiographically
apparent increase in the size or number of lesions (n = 12) or
histological diagnosis following lung resection (n = 12).
In the present study, only 16.3% of patients were diagnosed
with IPN on preoperative CT scan. The detection rate reported
in this study may be lower than those in previously published
reports as this study included only patients who were selected
for potentially curative hepatic resection and excluded patients
with calcified pulmonary lesions that usually suggest a benign
cause.20,21 Overall, this study indicated that 50% of patients with
IPN will ultimately demonstrate evidence of metastatic lung
disease, and that preoperative PET scanning in this group of
patients is of very limited help. Of the patients who developed
lung metastases, 60.0% were treated with palliative chemo-
therapy and 40.0% underwent lung resection. Maithel et al.
reported similar resection rates in patients in whom IPN pro-
gressed following hepatic resection.19
Previous studies have identified prognostic factors that may
predict the progression of IPN, including the presence of nodal
disease in the colorectal primary tumour18 and the absence of
calcification on lung nodules.19 With respect to the size of lung
nodules, previous studies have shown that solitary nodules and
nodules measuring 10 mm are more likely to be malignant,
and nodules sized 5 mm are usually benign in patients with
known malignancy.22 The present study included only CRLM
patients with IPN of <10 mm and without benign features such as
calcification, and hence specific features such as size and the
presence of calcification are not relevant in determining the
progression of these lung lesions. In addition, the majority of
patients in this study had solitary pulmonary lesions.
Positron emission tomography has been used in some centres
for preoperative staging prior to hepatic resection. Fernandez
et al. reported a 5-year overall survival rate of 58% following
hepatic resection for CRLM in patients who underwent preopera-
tive staging with PET.6 At present, the published data available to
determine the role of PET in the evaluation of subcentimetre IPN
are limited. Given that the threshold resolution of current PET
scanners is only 5–6 mm, it is unlikely that PET will provide useful
information on lung lesions that measure <5 mm. With respect to
lung nodules sized 5–10 mm, an increase in the uptake of these
lesions in PET is likely to indicate metastatic disease. However, a
negative PET result does not conclusively rule out underlying
metastases.23 O and colleagues observed that of 121 patients with
small pulmonary nodules that had minimal or no uptake on PET
imaging, 24 (20%) patients had underlying non-thoracic malig-
nancy.24 Previous studies have shown the progression of pulmo-
nary disease following hepatic resection for CRLM despite a
negative PET scan.19 In the current study, only six patients under-
went preoperative PET imaging prior to liver resection, and none
of them demonstrated IPN uptake suggestive of lung metastases.
Of these six patients, three patients subsequently did experience
progression of IPN suggestive of metastatic disease; two were
managed with palliative chemotherapy and the other underwent
lung resection. These results suggest that the role of PET imaging
in the evaluation of subcentimetre IPN remains to be determined.
Because of the difficulty in determining whether IPN may rep-
resent metastatic lung disease, the issue of whether patients should
be offered potential curative liver resection is controversial. It is
currently not acceptable to subject patients with resectable CRLM
to biopsy of the IPN as the small size of the latter poses consider-
able challenges in attempts to obtain an accurate biopsy by fine-
needle aspiration or video-assisted thoracoscopic surgery.25 This
practice may be associated with a high sampling error, risk for
seeding of tumour cells and morbidity related to these procedures.
Furthermore, in this study 50.0% of IPN cases were not malig-
nant. The present study showed no statistically significant differ-
ences with respect to disease-free and overall survival between
patients with and without IPN. Furthermore, there were no sig-
nificant differences in clinical, surgical and pathological factors
between the two groups of patients. This finding suggests that the
presence of IPN should not preclude patients with resectable
hepatic metastases from undergoing liver resection. This study
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Figure 3 Differences in overall survival in patients with and without
indeterminate pulmonary nodules (IPN)
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also emphasizes the importance of surveillance post-liver resec-
tion because the progression of IPN can be detected and a sub-
group of patients will have resectable lung disease that can be
potentially cured.
There are currently no guidelines for managing IPN in patients
with resectable CRLM. Because IPN is a common finding, an
algorithm for managing these patients has been proposed (Fig. 4).
In the present study, half of all patients with IPN ultimately pro-
gressed to metastatic lung disease, which suggests that this group
of patients requires intensive surveillance post-surgery. This prac-
tice can be justified as a subgroup of these patients will be suitable
for lung resection with curative intent. As the clinical variables and
radiological characteristics that help to differentiate benign from
malignant IPN in CRLM patients are limited, these patients
should be offered liver resection and should undergo an intensive
surveillance protocol as their survival is not significantly affected
by the presence of IPN.
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